Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
OBJECTIVE
The vascular damage systemic sclerosis (SSc) consists mainly of microvascular changes, but recently macrovascular changes with dyslipidemia were recognized. In systemic lupus erythematosus (SLE), autoantibody to lipoprotein lipase (LPL), a key enzyme that hydrolyzes triglycerides, suggested a role of autoimmunity for elevated serum triglyceride levels and atherosclerosis. We investigated the prevalence and levels of anti-LPL antibodies, their clinical correlation, and their functional significance in patients with SSc.


METHODS
Serum samples from patients with diffuse cutaneous SSc (dSSc; n = 55), limited cutaneous SSc (lSSc; n = 75), SLE (n = 21), and dermatomyositis (DM; n = 21) and healthy controls (n = 41) were examined by ELISA. The presence of anti-LPL antibody was evaluated by immunoblotting analysis using purified LPL. To determine the functional relevance of anti-LPL antibody in vivo, we assessed whether anti-LPL autoantibody was able to inhibit LPL activity using the LPL activity kit.


RESULTS
ELISA revealed that IgG or IgM anti-LPL antibodies were detected in 35% of SSc patients, while they were also positive in 67% of SLE patients and 43% of DM patients. The presence of IgG anti-LPL antibody was associated with elevated serum triglyceride levels, greater extent of skin fibrosis, and more frequent presence of lung fibrosis, heart involvement, and anti-topoisomerase I antibodies. The presence of anti-LPL autoantibody was confirmed by immunoblotting analysis. LPL activity was inhibited by IgG anti-LPL antibodies in sera from SSc patients with elevated serum triglyceride levels.


CONCLUSIONS
Our results suggest that anti-LPL autoantibody contributes to elevated serum triglyceride levels by inhibiting LPL enzyme activity in patients with SSc.
Kodera
Masanari
M
Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Hayakawa
Ikuko
I
Komura
Kazuhiro
K
Yanaba
Koichi
K
Hasegawa
Minoru
M
Takehara
Kazuhiko
K
Sato
Shinichi
S
D001323:Autoantibodies / Q000097:blood*; D003882:Dermatomyositis / Q000150:complications / Q000276:immunology / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications* / Q000473:pathology; D008071:Lipoprotein Lipase / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012595:Scleroderma, Systemic / Q000150:complications / Q000276:immunology / Q000473:pathology; D014280:Triglycerides / Q000097:blood*
D001323:Autoantibodies; D014280:Triglycerides; D008071:Lipoprotein Lipase